Collaboration to Combine siRNA and Reverse Transfection

A research collaboration to study the utility of combining small interference (si) RNA-mediated gene silencing with whole-well reverse transfecton has been announced by Dharmacon, Inc. (Lafayette, CO, USA) and Akceli, Inc. (Cambridge, MA, USA).

Akceli's reverse transfection technology provides a high throughput process for delivering nucleic acids to mammalian cells, increasing the speed and simplicity of introducing foreign nucleic acids into cells and analyzing the subsequent cellular effects. Dharmacon uses its Smart selection and Smart pool technologies to produce synthetic siRNA reagents guaranteed to silence target genes with a high degree of potency and specificity. Together, the technologies of the two companies may accelerate the analysis of gene function, cellular pathways, and networks.

Under the terms of the agreement, Dharmacon will supply specified siRNA reagents developed with its Smart selection and Smart pool technologies, and Akceli will provide reverse transfection materials and carry out the experiments. The results of the studies conducted will be used to validate the efficacy of whole-well siRNA reverse transfection and its utility for transfection optimization.

"Our combined technologies have the potential to significantly expand the utility of siRNA-mediated gene silencing in functional genomics and drug discovery research,” said Stephen A. Scaringe, co-chairman and chief scientific officer of Dharmacon.





Related Links:
Dharmacon
Akceli